Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Presentation: http://wsw.com/webcast/roth30/galt/index.aspx
September will bring data on the NASH FX and Psoriasis GT-030.
Recent publication in Newsweek jan 2016.
Discussion on the Gilead Simtuzumab.
20$ cost a dose (very cheap).
Liver Multiscan to be used in the test - improvement from biopsy.
Cash might last until early next year - by which time, good top line results from either test might fetch better valuations.
This one needs patience.
And lose some weight. You dont want to be GALT client.
:)
Didn't have the chance to study it properly, but did notice the new contacts were below my expectations for the high season. If the next quarter is as low it may hint to a slowing of sales growth. The thesis is fast adoption by a welcoming farmer community. With expended sales force these results seems off.
The good doctor is a master in choosing word and if validation is absent, it would not be the first time he purposely chose to remain vague to paint a rosier picture than reality, so your criticism is certainly a Fair one, I am sorry to acknowledge.
Apparently CEO just confirmed 500 grams production to an Agora analyst. Convinced a serious skeptic there is value. At least one to two years away from rev., though NNVC brass ability to set and meet deadlines is historically the best comedy in town.
The 2 CEOs:
Mike west is now in to :"...manage the Company’s science, technology development, and intellectual property activities, including the advancement of its discovery and pre-clinical product development programs."
Aditya Mohanty, the other CEO is in going to "...manage the Company’s corporate strategy and development and implementation, manage product development post early stage, oversee routine operations, and serve as the main contact for institutional investors "- basically all the rest
WEST gets a CO-CEO.
Why?
Is the Board getting restless?
Is WEST incapable of doing his job?
This raises many questions and may point to major changes down the road.
I'll be following developments closely.
Patrick's hopeless in assessing things like management or financing skills. He does a fair job in assessing technology.
Even he himself does invest in perhaps 3 to 5 ideas from his picking, when real money is on the table, not think ISCO is in that group.
Remember he has to rec. every month. Who can find winners every month?
One a year will make you a millionaire...
This financing is of a very sic & desperate company. Also, it feels like Jim & company are shell shocked by the market reaction to their comments and what they perceive to be an attack on the pps, to the degree they fail to properly present the investment community of the company. I know BTA editor reaches out to get data from the company, his deciding P 1 failed is an example of fear to communicate to the public.
TESAs move is against corporations that have no activity in Israel, listing in Tel Aviv and getting uplift from Index buying.
The fact is that BIo Time has several activities In Israel including Clinical Tests in Hadassa Hospital in Jerusalem.
No big deal.
The financing terms are of extra weak company. Who is the broker? Maxim? I cheer for the firm but the situation is dire.
OncoCyte spinoff this quarter. With 20% short interest, where is BTX and the spinoff going?
Yup. Several things come to mind looking at the recent press release:
a. They got deals done even in the slowest season of the year. I would imagine most farmers are busy as hell in this quarter.
b. Extention deals, either in leangth or add on land suggests the service is value added to clients. It also somewhat confirms the stickyness of the service. Repeat sales is a very powerful force and tends to add spring to a growing business.
c. The company used most of the funds incoming to reinvest in new contracts - a very powerful component in the compounding of revenues and profits.
Next up are the quarterly reports to confirm. In the next 2 quarters we will find out the actual rate of signing up of new contracts with the added sales force.
I am very optimistic and very happy to see the results.
Further down the line, the company might choose to sell at least some of the RapeSeeds later in the year to lock in higher rates, but I do believe for now, as fast as funds come in, they are better of being reinvested in new contracts, as far as the demand is there.
All in All - great job so far.
Adi.
Great Forbes Article: http://tinyurl.com/mwl5zlf
sticky clients, not a pinky anymore, and massive future in ~30 billion gambling industry, not to mention the potential of Social Games - Years of massively profitable growth ahead (>40% Ebitda), ALL trading at a very good price.
20$ is soon going to be a distant memory.
I recall Czzir stating they hope the shorter test positive results might push the valuations back to realistic value and open additional funding opportunities.
19ish. This is going way higher, with insiders having this track record. If you found it this early, congrats. Enjoy the ride up!
Why investors fail:
They let emotions (read:panic) control their investment.
If you DID your DD, and you thought the upside was terrific at 3.0$, 2.5$, 2.0$, you should be shivering with greed at <1.7$. Period. Most likely, adding to a greatly undervalued asset.
If you didn't do your DD, or was not convinced of the upside, your gambling.
I have yet to see any significant data to change my investment thesis, and do thank the gamblers/shorters for a blue light special.
Now, if they could just keep at it, I do have a big pile of cash to deploy at 1.1$.
For the rest of the longs, the gamblers will come back @ much higher prices, to try get 100% gain instead 1000%.
For a good case study, drop by at CSU.T board. See how traders made a buck and lost 460$C on 25$c investment...
Keep cool. This is microcap biotech.
The only question is if pps is higher than strike at the end. Since revenues are still somewhat distant and the pps is volatile it might be better to own the equity, esp. In the low 3's, giving unlimited time for the thesis to play out.
Want to see something funny about traders? Go to the constellation software CSU board and check out the date and share price of the company at the time they were trading and calculate how many millions they lost by not holding tight...
Back at the levels it started trading at. I'm seriously tempted, though BTX might be the better value. I can't see BTX offloading their stake.
It's been tough for longs.
However, investors, not traders, look at the big picture: science progress, finance, etc.
The science is moving along fine. If it shows good results by next year, before new financing round grows near, we could see 3-5 bill. Market cap.
Should that occur, longs will be very happy.
Until that time, it's waiting game.
Totally divesting of AST is strange. It would mean West et al don't believe the future cash flows trump significantly the current market cap and instead believe in the short term products BTX companies have.
Or the price of new funds is too steep.
Interesting.
I would like to know his rational
Is the growth in rev. Going to accelerate?
What a terrible financial management...
While the idea in general looks interesting, I am not even sure the execs know how to model repeat sale revenues and certainly don't voice any opinions from what I found.
The long warrants look fitting.
Could be. I don't know and don't try to read the tea leaves. There will be many more high volume drops in the future. Short term traders and speculators will find infinity or reasons to short or exit. There will be dilutions up at BTX and down in the daughter corporations, as well as general market swings.
What we longs see is huge IP, great clinical trials, good financial management, value making dilution and infinitely wide ways to succeed.
Intel of stem cell medicine.
More sellers than buyers?
This is still very early for BTX. Lots of potential, but until some new products pull in cash from sales, PPS will swing wildly.
The potential is immense. But we still have some time ahead of us to calm PPS movement.
Costs of trials, financing plans, what sort of deal are they looking for or think is appropriate if results of the shorter test (Fx?) is good.
They are at phase 2b...
Thanks. If so, Tesla1, we just lost a potential possible competitor, for the time being, or so it seems.
It may be that La Jolla Pharmaceutical (NASDAQ:LJPC) is to be applauded for cutting its losses and ditching its two kidney disease candidates GCS-100 and LJPC-1010 after the FDA insisted on the kind of chemical composition data that would have been hard and expensive to acquire. Shareholders, though, were disappointed, sending its shares down 15% to $16.49 on Friday.
LJPC 1010 was gelactine 3 inhibitor from oranges. Ours - Apples.
It is highly likely the FDA will ask us the same thing.
Any idea about the cost or what are the ricks we can get similar request?
My 'stinker' order filled at 2.86, at a significant amount. Unbelievable to have gotten it. I'm fully invested now. Up, Up and away.
September GTV split. GTV 100% rev growth. Sum of parts valuation 11$, at 6.6$ you buy a dollar for 54 cents. This is worth way more than it trades for and management is taking all the right steps.
We almost saw a major short squeeze recently. Over 30% of the float is shorted, so some people have lots to lose from PPS going up.
Look out for some fireworks as The news roll out this year with respect to all the irons in the fire.
Also do the math yourself, net of Asterias part 70%, Biotime never traded that cheap.
In ten years time buying here will be a Big Fish tale!
OncoCyte Announces Availability of Abstracts With New Clinical Data From Studies of PanC-DxTM Cancer Diagnostic in Bladder and Breast Cancer
Date(s): 20-Mar-2015 8:00 AM
For a complete listing of our news releases, please click here
Data to be Presented at American Association for Cancer Research 2015 Annual Meeting
ALAMEDA, Calif.--(BUSINESS WIRE)--Mar. 20, 2015-- BioTime, Inc. (NYSE MKT:BTX) and its subsidiary OncoCyte Corporation today announced the online availability of abstracts providing human clinical data highlighting the potential of PanC-DxTM, OncoCyte's class of non-invasive cancer diagnostics based on OncoCyte's proprietary set of cancer markers. These markers were discovered by company scientists through an analysis of broad gene expression patterns in numerous cancer types. These markers, including COL10A1, are the subject of multiple pending patent claims filed in numerous countries worldwide and are owned by OncoCyte. Data included in the abstracts will be presented in two poster presentations at the American Association for Cancer Research (AACR) Annual Meeting being held April 18-22, 2015.
"The presentations on PanC-DxTM at the AACR 2015 annual meeting will report on the first human clinical data from a key OncoCyte product development program," said Joseph Wagner, PhD, OncoCyte's Chief Executive Officer. "We, along with our clinical investigators, are pleased with the high sensitivity and specificity of PanC-Dx in diagnosing bladder cancer. The levels of accuracy that we report may give this new diagnostic the potential for widespread adoption as an improved method of detecting bladder cancer or its recurrence. We appreciate the effort of our clinical investigators and distinguished collaborators at Johns Hopkins University School of Medicine, leaders in bladder cancer research."
The first abstract describes the clinical data and assay development progress of OncoCyte's bladder cancer diagnostic test. Data obtained from a clinical study recently completed in collaboration with investigators in the Department of Pathology at Johns Hopkins University School of Medicine, was to assess the performance of OncoCyte's proprietary diagnostic technology in detecting the most common type of bladder cancer, urothelial carcinoma (UC). Study investigators collected 90 urine samples from patients undergoing urine cytology for the diagnosis of either primary or recurrent bladder cancer. An analysis was performed and a panel of markers that discriminates UC from non-cancerous conditions was identified. Evaluation of the performance of this gene panel indicated high levels of sensitivity and specificity (Receiver Operating Characteristic area under the curve of greater than 0.9). Additional evaluation of this gene panel in the context of a larger multi-site study is ongoing and results from this expanded clinical study will be included in the presentation.
The second presentation will provide a summary of the clinical data and assay development progress of OncoCyte's breast cancer diagnostic test. Specifically, the abstract describes the potential utility of COL10A1 as a blood-based biomarker for multiple cancers, including breast cancer. This study involving over 600 patients is being conducted at Scottsdale Medical Imaging Laboratories.
Overall markets for bladder cancer diagnostics are large and growing. Based on National Cancer Institute statistics, it was estimated that in 2015 over 74,000 new cases of bladder cancer would occur in the United States and a total of over 500,000 men and women alive would have a history of bladder cancer and be subject to recurrence surveillance testing using cystoscopy or urine cytology. Bladder cancer has the highest recurrence rate of any major type of cancer; recurrence surveillance testing is strongly recommended and widely performed.
In 2010, over 30 million screening mammograms were performed in the US alone. The American Cancer Society and the National Comprehensive Cancer Network both recommend screening mammography every year starting at age 40, which has been associated with relative reduction in breast cancer mortality of 15% to 20%. However, the NCI estimates that approximately 20% of all breast cancers are not detected by mammography during annual screening which indicates there is an unmet need for a breast-cancer screening test with superior specificity and sensitivity when compared to standard screening mammography.
Details for the two poster presentations are as follows:
Presentation Title: Identification of gene-expression biomarkers in urine pathology specimens for the detection of bladder cancer
Abstract #: 551
Location: Poster Section 23
Poster Board Number: Board 21
Date & Time: Sunday, April 19, 2015 at 1:00 PM - 5:00 PM EDT
Presentation Title: Identification of type X collagen as a pan-cancer serum biomarker
Abstract #: 1578
Location: Poster Section 22
Poster Board Number: Board 18
Date & Time: Monday, April 20, 2015, 8:00 AM - 12:00 PM EDT
CEO aggressively buying and holding. Great platform though not much to look for this year, next will be interesting.
Much depends on the results of the FX trial. With even medium results published by q3 2016, the warrants could provide a good source of dilution. I sure hope there will be indications before hand. Overall and in spite of the lack of transparency, I am an optimist, especially from about 85 million cap and 23ish million shares outstanding. Seems 5 billion cap is not too hard to model, like ICPT.
What a ride!
GLTA
Thanks biotech. Your input is very welcome.
While BTX has many, many irons in the fire and good management to boot, no one knows when the catalysts will arrive. There is still plenty risk. Therefore, the warrants are too close for my comfort. The share price for me is like a long call without expiration. Getting caught with too little time on this kind of position is not very helpful.
Buy in third and wait for more progress to add, I would recommend.
Do the math yourself. They are ways a way from that. This Co. is going to continue to dilute shareholders until that time. Any current shareholder takes that into consideration. The time to buy will be when there are clues they near brake even.
Pshhhhh.....
All the traders that played for a buck gone. Lost out the whole tour from 22 to over 300. Typical.
This is one gem. I have never seen someone manages his business that good.
Still studying it but thinking of opening a position here.
Anyone has any thought about potential?
Waiting to see the phase 2 format. They say they are going for multiple indications, which might be more expensive that what I thought initially.
Funding at this low level might be somewhat dilutive, albeit the share count is low now.
Let's see.
Thanks for the write up. By any chance, did they elaborate on the scale up process? Did they explain where they were at the process now, and how long it takes to make 200 batch now